Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
South Korea’s leading biologics companies will invest hundreds of billions of won to building additional plants that would push the total amount of private investments for the biohealth industry to 10 trillion won by 2023.
Samsung Biologics will pour 1.7 trillion won into its new Plant 4 while Celltrion will invest 500 billion won to its Global Life Science Research Lab and Plant 3, all in Songdo, Incheon.
As its action plan for a more robust bio-industry ecosystem, the Government also pledged a 1.7 trillion won budget in 2021, up 30 percent from last year’s. The budget will prioritize pharmaceuticals, medical devices, and digital health care.
Biohealth players are building an ecosystem for biologics in Songdo, which now hosts 60 South Korean and international bio-related companies, employing around 7,000.
About 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms by 2023.
It would boost manufacturing capacity by 20 percent and employ an additional 9,300.
The government envisions the biologics workforce to grow to 47,000 by 2025 in a joint effort with the academe.
The regional bio clusters of Songdo, Wonju in Gangwon Province, Osong in North Chungcheong Province, and Daegu will increase collaboration.
The biologics industry is globally increasing 4 percent annually, higher than shipbuilders at 2.9 percent and car manufacturers at 1.5 percent.
